Linagliptin

Linagliptin is used in Diabetes Mellitis for glycemic control as a monotherapy as well as in combination with other antidiabetic drugs Linagliptin is an inhibitor of enzyme DPP-4 (Dipeptidyl peptidase 4) thereby regulating the activation of hormones GLP-1,GLP .Thus regulates glucose hemeostasis

Brands
Adult Dose
Dose: 5 to 5 mg
Single Dose: 5 (5)
Frequency: 24 hourly
Route: PO
Instructions: when we administer this drug with metformin and sulfonylurea the dose of metformin and sulfonylurea should be maintained.no double dose should be taken on the same day
Neonatal
Paedriatic
Characteristics
It belongs to Antidiabetic Agent pharmacological group.
Contraindications
Linagliptin is contraindicated in conditions like Hypersensitivity.
Effects
Linagliptin produces potentially life-threatening effects which include Hypoglycemia, Hypoglycemia. which are responsible for the discontinuation of Linagliptin therapy.The symptomatic adverse reactions produced by Linagliptin are more or less tolerable and if they become severe, they can be treated symptomatically, these include Cough, Hypersensitivity, Hypoglycemia, Pancreatitis, Nasopharyngitis.
Indications
Linagliptin is primarily indicated in conditions like Diabetes mellitus type-ii.
Interactions
No data regarding the interactions of Linagliptin was found.
Interfrence
Risks
Drug should not be given to Paediatrics, Pregnant Mothers, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Geriatrics.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Warnings
It should not be used for the treatment of Diabetes type 1 or or for treatment of diabetic ketoacidoses.Caution is advised when the drug is given with sulfonylurea due to the risk of hypoglycemia
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.